Context: Breast development is a key feature of feminization and therefore important to transwomen male-to-female transgender persons. It is not exactly known when breast development starts after initiating cross-sex hormone therapy CHT and how much growth may be expected. Objective: To investigate breast development in transwomen during their first year of CHT and whether clinical or laboratory parameters predict breast development.
Use the link below to share a full-text version of this article with your friends and colleagues. Learn more. If you have previously obtained access with your personal account, Please log in.
Transgender women — people who are born with male genitalia but who identify with the female gender — who take feminizing hormone therapy have a higher risk of breast cancer compared to the average man, according to a Dutch study. The results also found that transgender men — people who are born with female genitalia but who identify with the male gender — who take masculine hormones have a lower risk of breast cancer than the average woman. The research was published online on May 14,by the journal BMJ.
Back to Gender dysphoria. Treatment for gender dysphoria aims to help people with the condition live the way they want to, in their preferred gender identity. What this means will vary from person to person, and is different for children, young people and adults. Read about how to find an NHS gender identity clinic.
Breast development is a key feature of feminization and therefore important to transwomen male-to-female transgender persons. It is not exactly known when breast development starts after initiating cross-sex hormone therapy CHT and how much growth may be expected. To investigate breast development in transwomen during their first year of CHT and whether clinical or laboratory parameters predict breast development.
The goals of feminizing hormone therapy are to raise the estrogen level and to lower the testosterone level so that both levels are in the normal, physiologic female range. There are three different kinds of medications that are typically used: estrogen, testosterone blockers, and progesterone. Estrogen is the hormone responsible for most feminine characteristics.
Transgender hormone therapy of the male-to-female MTF type, also known as feminizing hormone therapyis hormone therapy and sex reassignment therapy to change the secondary sexual characteristics of transgender people from masculine or androgynous to feminine. Some intersex people also take this form of therapy, according to their personal needs and preferences. The purpose of the therapy is to cause the development of the secondary sex characteristics of the desired sexsuch as breasts and a feminine pattern of hairfatand muscle distribution.
Purpose: Defining the risk of neoplasia associated with gender-affirming hormone therapy GAHT is a priority for transgender medical research. The purposes of this article are to present a unique case of breast neoplasia in a transgender individual and to review the existing evidence base on GAHT as a potential risk for breast pathology. Methods: We present the case of a year-old transgender patient who developed an estrogen receptor-positive mammary myofibroblastoma MFB after 13 months of treatment on feminizing hormones.
Feminizing hormone therapy is used to induce physical changes in your body caused by female hormones during puberty secondary sex characteristics to promote the matching of your gender identity and your body gender congruence. If feminizing hormone therapy is started before the changes of male puberty begin, male secondary sex characteristics, such as increased body hair and changes in voice pitch, can be avoided. Feminizing hormone therapy is also referred to as cross-sex hormone therapy.